Upjohn Caverject injection for erectile dysfunction to reach pharmacy shelves by August.
Executive Summary
UPJOHN CAVERJECT TO REACH PHARMACY SHELVES BY LATE AUGUST following FDA marketing approval July 6. Alprostadil sterile powder is indicated for the diagnosis and treatment of male erectile dysfunction due to neurologic, vascular, psychological or mixed causes. "Caverject may be a useful adjunct to other diagnostic tests in the diagnosis of erectile dysfunction," labeling adds. Caverject is the first prescription medication for erectile dysfunction approved in the U.S. The NDA for Caverject was filed in February 1994.